Security Snapshot

Aptose Biosciences Inc. - Common Shares Institutional Ownership

CUSIP: 03835T200

13F Institutional Holders and Ownership History from Q4 2014 to Q1 2025

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Shares outstanding
2,556,332
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • 03835T200 - Aptose Biosciences Inc. - Common Shares is tracked under CUSIP 03835T200.
  • Latest finished 13F holder period is not available.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 2 to 0 between Q4 2024 and Q1 2025.
  • SEC-reported value moved from $4,414 to $0.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

03835T200

Latest holder period

n/a

13F holders

13D/G owners

1

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
1
Security
03835T200
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Hanmi Pharmaceutical Co., Ltd. 20% $115,375 508,710 Hanmi Pharmaceutical Co., Ltd. 18 Mar 2025

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
42
Latest
n/a
Rows shown
1-25 of 42
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q1 0 $0 -$4,414 0
2024 Q4 19,592 $4,414 +$4,393 $0.23 2
2024 Q3 92 $38 $0.41 1
2024 Q2 92 $70 -$44,000 $0.76 1
2024 Q1 26,758 $44,153 -$79,202 $1.66 2
2023 Q4 74,758 $188,234 $2.53 2
2023 Q3 74,758 $209,258 +$59,717 $2.80 2
2023 Q2 53,424 $247,427 -$16,354,051 $4.64 2
2023 Q1 20,962,406 $13,416,873 -$1,028,939 $0.64 44
2022 Q4 22,970,643 $13,320,850 -$985,663 $0.58 48
2022 Q3 24,557,699 $14,615,453 -$318,301 $0.60 47
2022 Q2 25,058,806 $18,646,507 -$2,734,410 $0.74 43
2022 Q1 28,531,682 $38,807,613 -$3,580,687 $1.36 51
2021 Q4 31,179,158 $42,369,792 -$20,800,165 $1.35 57
2021 Q3 39,570,451 $86,350,850 -$22,510,362 $2.18 63
2021 Q2 47,225,004 $156,739,083 -$38,364,376 $3.32 62
2021 Q1 52,369,697 $312,930,503 +$27,233,992 $5.98 71
2020 Q4 48,718,160 $213,602,858 -$10,658,227 $4.38 65
2020 Q3 46,407,177 $278,292,363 +$62,519,881 $6.00 64
2020 Q2 35,924,634 $226,542,479 +$5,200,153 $6.31 57
2020 Q1 34,928,326 $207,138,467 +$26,188,083 $5.94 52
2019 Q4 30,725,365 $174,227,455 +$81,216,464 $5.67 56
2019 Q3 14,207,658 $29,579,615 +$4,633,211 $2.08 31
2019 Q2 11,921,350 $31,121,540 +$22,562,599 $2.61 29
2019 Q1 3,295,238 $6,621,532 +$429,262 $2.00 21
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .